Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma

Plain-language summary

This study examines the role of changes in the RPL8 protein in high-grade serous ovarian carcinoma. It enrolls people aged 18 and older with high-grade (grade 3 or 4) serous ovarian carcinoma, either at first diagnosis or recurrence. It is a non-phase study and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Start date

3/20/2024

Estimated completion

8/30/2025

Countries

Italy

Related genes

Locations

• Bologna, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age ≥ 18 years.
* Diagnosis of high-grade (3 or 4) serous ovarian carcinoma, either at onset or recurrence.
* Signed informed consent to participate in the study.

Exclusion Criteria:

* Ovarian tumors of histological types other than serous.
* Other primary tumor types.